Aridis Pharmaceuticals, Inc.

OTCPK:ARDS Stock Report

Market Cap: US$5.3k

Aridis Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Vu Truong

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure21.9yrs
CEO ownership2.6%
Management average tenureno data
Board average tenure8.4yrs

Recent management updates

Recent updates

Aridis Pharmaceuticals announces proposed public stock offering; shares down ~30%

Sep 26

Aridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29M

Aug 16

Can You Imagine How Aridis Pharmaceuticals' (NASDAQ:ARDS) Shareholders Feel About The 32% Share Price Increase?

Feb 17
Can You Imagine How Aridis Pharmaceuticals' (NASDAQ:ARDS) Shareholders Feel About The 32% Share Price Increase?

Aridis Pharmaceuticals EPS misses by $0.02

Nov 20

Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow

Oct 31

CEO Compensation Analysis

How has Vu Truong's remuneration changed compared to Aridis Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$1m

Jun 30 2023n/an/a

-US$9m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$753kUS$525k

-US$30m

Sep 30 2022n/an/a

-US$33m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021US$842kUS$500k

-US$46m

Sep 30 2021n/an/a

-US$43m

Jun 30 2021n/an/a

-US$25m

Mar 31 2021n/an/a

-US$24m

Dec 31 2020US$783kUS$475k

-US$22m

Sep 30 2020n/an/a

-US$22m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$2mUS$450k

-US$30m

Sep 30 2019n/an/a

-US$29m

Jun 30 2019n/an/a

-US$30m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$2mUS$450k

-US$23m

Compensation vs Market: Insufficient data to establish whether Vu's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Vu's compensation has been consistent with company performance over the past year.

CEO

Vu Truong (60 yo)

21.9yrs

Tenure

US$752,516

Compensation

Dr. Vu L. Truong, Ph D., is the Founder at Aridis Pharmaceuticals, Inc. and also serves as its Chief Executive Officer and Chief Scientific Officer since 2003. He has more than 15 years of experience in b...

Board Members

NamePositionTenureCompensationOwnership
Eric Patzer
Founder & Executive Chairman19.9yrsUS$262.80k1.66%
$ 88.5
Vu Truong
Founder10.9yrsUS$752.52k2.59%
$ 137.9
John Patton
Member of the Scientific Advisory Boardno datano datano data
John Hamilton
Independent Director9.5yrsUS$40.50k0.0037%
$ 0.2
Harry Greenberg
Member of Scientific Advisory Boardno datano datano data
Susan Windham-Bannister
Independent Director5.5yrsUS$37.50k0%
$ 0
Marin Kollef
Member of Clinical Advisory Board8.4yrsno datano data
Alan Cohen
Member of Clinical Advisory Boardno dataUS$703.17kno data
Jerry Pier
Member of the Scientific Advisory Boardno datano datano data
Steven Opal
Member Scientific Advisory Boardno datano datano data
Bruno Francois
Member of Clinical Advisory Board8.4yrsno datano data
Jean Chastre
Member of Clinical Advisory Board8.4yrsno datano data

8.4yrs

Average Tenure

73yo

Average Age

Experienced Board: ARDS's board of directors are considered experienced (8.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 22:51
End of Day Share Price 2024/12/31 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aridis Pharmaceuticals, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Louise ChenCantor Fitzgerald & Co.
Vernon BernardinoH.C. Wainwright & Co.
François BriseboisLaidlaw & Company (UK) Ltd